The Software Monopoly That Owns Drug Development and Is About to Own AI

While headlines chase the next AI darling, we’re digging into a $45 billion software monopoly that the market has stopped paying attention to.

It raised guidance, keeps landing the biggest drug companies on the planet, and has an AI product that hasn’t contributed a single dollar to revenue yet.

Today we break down why the setup is worth your attention, plus a few movers to watch.

The Healthcare Software Leader the Market Forgot to Price

Veeva Systems (NYSE: VEEV) raised guidance, landed more of the world’s biggest drug companies, and the stock went absolutely nowhere.

The market has been selling anything with a high multiple, and Veeva got caught in that rotation. A sentiment problem dressed up as a valuation concern, and you have seen this movie before.

Here’s the gap worth locking onto. The AI product that management has been building hasn’t contributed a single dollar to revenue yet. When it does, the math on this business shifts in a way the current price doesn’t reflect. That’s the part the crowd is sleeping on.

The quarter the market shrugged at

Veeva Systems (NYSE: VEEV) put up a strong quarter. Revenue grew nearly 18% year over year, earnings cleared analyst expectations by a comfortable margin, and net margins held above 29%.

A business firing on most cylinders, executing through a major platform transition, and holding the line on profitability.

Management moved the bar higher

After the beat, leadership raised full-year revenue guidance and guided the current quarter above prior expectations. Raising after a beat is the signal you want.

It tells you the quarter wasn’t a fluke, and the team is confident enough to put a higher number on the board. The market barely reacted. That’s your opening.

It’s woven into every major drug company’s walls

Veeva runs the operating infrastructure for life sciences. Clinical trials, regulatory filings, quality management, commercial operations.

Over 1,500 customers across pharma, biotech, and medical devices run on its Vault platform, and the biggest names in the industry are locked in.

Switching costs here are brutal. A top-20 drug company that has built its entire regulatory and development workflow on Veeva Vault is not going to rip it out.

The cost, the compliance risk, the retraining: all of it is prohibitive. Customers that get in tend to stay in and spend more over time. That stickiness is what you’re buying when you buy VEEV.

Taking back the commercial stack

For years, Veeva ran its commercial CRM on top of Salesforce’s infrastructure, a structural vulnerability hiding inside an otherwise clean business.

Now Veeva is migrating customers onto Vault CRM, its own platform, and the migration is working.

Over 190 customers are already live, and 14 of the top 20 biopharmas have committed. Owning the full stack removes a long-standing competitive risk and sets up higher customer lifetime value going forward.

Falcon is sitting at the starting line

Veeva is rolling out an agentic AI product called Falcon that operates directly inside its Vault applications on drug development workflows. It handles routine processing and escalates to humans only when it actually needs to.

For a pharma company spending hundreds of millions managing data and compliance, that’s a genuine cost-saving product, built into infrastructure the customer already depends on.

Here’s the part that should have your attention: management hasn’t put any revenue guidance around Falcon yet.

Every dollar it eventually generates lands as upside that isn’t in the current numbers. You’re not paying for it today. That’s a strange position to be in for a product this close to launch.

The data foundation nobody can replicate

Veeva’s clinical data platform has processed information for over a million trial subjects across more than a thousand studies. That’s the proprietary data layer that gives its AI products a real edge. A competitor can’t buy its way to that scale.

It takes years to build. When Falcon starts converting customers, the revenue it generates sits on top of a moat that took a decade to assemble.

Emerging biotechs are standardizing on Veeva from day one

Over 175 emerging biotech companies have now standardized on Veeva Basics, the entry-level pre-configured suite. These aren’t small accounts to ignore.

They’re companies at the beginning of their growth trajectories, building their regulatory and clinical workflows on Veeva’s infrastructure from the start, before they become the mid-size and large pharma accounts of tomorrow.

The land-and-expand engine

A company that starts on Basics and grows into a serious mid-sized biotech doesn’t go looking for a new vendor. It expands across the same Vault platform it’s already running on.

Veeva gets the customer early, builds the relationship, and scales with them. Each new emerging biotech that commits today is a long-term revenue opportunity that isn’t fully showing up in what you see right now.

Net income grew sharply compared to the same quarter a year ago, and that headline figure has been making the rounds.

Worth knowing: the year-ago quarter included a meaningful litigation settlement charge that depressed the baseline. The year-over-year comparison is flattering the headline.

Strip that out and what you get is non-GAAP operating margins running essentially flat year over year, just under 45%. Still excellent.

A highly profitable business with consistent margins, so don’t read the headline jump as evidence of some sudden profitability breakthrough. The underlying trend is solid and stable, which at the multiple VEEV carries, is exactly what you want.

The multiple is unforgiving. At around 30x forward earnings, any guidance reduction hits twice: once from the earnings cut and again from multiple compression.

The stock has shown it can sell off hard when sentiment shifts, even when the fundamentals are intact. Keep that in mind when sizing your position.

The Vault CRM migration is going well, but it isn’t finished. If a major customer hits a problem mid-transition or delays its commitment, the market won’t be patient about it. The track record so far is clean, but it’s worth watching.

Falcon has to convert. Attach rates and deal sizes are still unknown. If early adoption comes in softer than what the market starts pricing in, the re-rating case loses its engine.

Salesforce knows exactly what Veeva is doing. It’s building life sciences capabilities of its own and carries deep relationships with enterprise IT at major pharma companies. That competitive dynamic isn’t fully resolved.

A dominant business in a segment where dominance is genuinely durable, sitting below its recent high for reasons that have nothing to do with how the company is performing. The CRM migration is working.

The emerging biotech tier is growing. And there’s an AI product with zero revenue in the numbers yet, built on top of a proprietary data moat that took years to assemble.

The average analyst price target barely clears where the stock is trading today.

The Street has already made its easy consensus money, and the next leg of upside depends on AI monetization that hasn’t started yet. If you’re waiting for permission from the sell-side, you’ll be buying in after the stock has already moved.

The entry window is open, and the thesis is clean. Set a mental stop around $255. If the stock breaks through that level on fundamental news, reassess. Otherwise, the business is executing, and the setup is intact.

Entry zone: $275 to $290. Add on weakness toward $265. Target: $360 to $385 over 9 to 15 months. Confidence: high.

Looking to buy? The stock has been consolidating, and that’s your window. Start a position in the $275 to $290 range. If it breaks out before you get in, wait for the next pullback rather than chasing it.

Already own it? Hold. The next earnings call is your key checkpoint. Listen for early commentary on Falcon traction and the pace of Vault CRM additions. Those are the two signals that move the thesis forward or back.

Main risk to respect: A guidance cut would hit this stock harder than most at this multiple. Size your position at something you can hold through a 15 to 20% drawdown without making emotional decisions.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any value stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge